Clinical Trial

A Study to Evaluate the Efficacy and Safety of Bimekizumab Compared to Ustekinumab in Children and Adolescents From 6 Years to Less Than 18 Years of Age With Moderate to Severe Plaque Psoriasis

Study acronym: BE TOGETHER
Active, Not Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
The primary purpose of this study is to evaluate the efficacy of bimekizumab administered subcutaneously (sc) compared to active control (ustekinumab) in children and adolescents aged 6 to \<18 years of age with moderate to severe plaque psoriasis (PSO).
Protocol Amendment History 2 changes
critical Enrollment closed, study ongoing 2026-08-08
notable Trial sites reduced: 50 -> 42 locations 2026-08-08
Trial Details
NCT Number NCT06425549
Lead Sponsor UCB Biopharma SRL
Conditions Moderate to Severe Plaque Psoriasis
Enrollment 175 participants
Start Date 2024-06-25
Primary Completion 2028-08-21 (estimated)
Study Completion 2030-11-08 (estimated)
Updated on ClinicalTrials.gov 2026-08-14